Boehringer and Lonza question the future of FDA's regulation of AI in manufacturing
The FDA opened the floor for comments on its discussion paper on the use of AI in drug manufacturing, with interest groups and manufacturers in the US and Europe submitting tweaks to the agency.
The discussion paper on AI in drug manufacturing focused on issues like cloud applications for data, the need for more clarity about how AI is subject to regulatory oversight, and the need for validating AI models.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters